AXCELLA TO PRESENT AT THE BMO CAPITAL MARKETS 2016 PRESCRIPTIONS FOR SUCCESS HEALTHCARE CONFERENCE
CAMBRIDGE, Mass., Dec. 7, 2016 – Axcella, a biotechnology company pioneering transformative medicines for patients with conditions where disrupted amino acid biology plays a critical role, announced today that Robert Connelly, President and Chief Executive Officer, will present a company overview at the BMO Capital Markets 2016 Prescriptions for Success Healthcare Conference in New York, N.Y. The presentation will take place December 14, 2016, at 11:20 a.m. EST.
Axcella is pioneering revolutionary new medicines with a focus on amino acid homeostasis. The company has identified more than 2,000 diseases with amino acid imbalances and developed a systems pharmacology approach to restore health at the cellular level. Axcella’s proprietary platform is clinically validated across several indication areas, with clinical-stage candidates in metabolic (liver, muscle) and neurodegenerative conditions. Axcella is led by a team with a strong track record of leaving a lasting impact on the therapeutic landscape through the development of novel products. The company was founded by VentureLabs, the Innovation Foundry at Flagship Ventures, and has received additional funding from Fidelity Research & Management Group, Gurnet Point Capital and Nestlé Health Science. Axcella is based in Cambridge, Mass. For more information, visit www.axcellahealth.com.